

Matthew Wallis  
Anne Tarvidon  
Thomas Helbich  
Ingrid Schreer

## Guidelines from the European Society of Breast Imaging for diagnostic interventional breast procedures

Published online: 30 September 2006  
© Springer-Verlag 2006

On behalf of EUSOBI Committee (see: <http://www.eusobi.org>).

M. Wallis (✉)  
Warwickshire, Solihull & Coventry  
Breast Screening Service,  
University Hospital,  
Clifford Bridge Road,  
Coventry CV2 2DX, UK  
e-mail: [Matthew.wallis@uhcw.nhs.uk](mailto:Matthew.wallis@uhcw.nhs.uk)  
Tel.: +44-2476967169  
Fax: +44-2476967180

A. Tarvidon  
Department of Radiology,  
Institut Curie,  
26, rue d'Ulm,  
75248 Paris, France  
e-mail: [anne.tarvidon@curie.net](mailto:anne.tarvidon@curie.net)  
Tel.: +33-1-44324200  
Fax: +33-1-44324015

T. Helbich  
Department of Radiology,  
Medical University Vienna-AKH Wien,  
Waehringerguertel 18–20 1090,  
Vienna, Austria  
e-mail: [thomas.helbich@meduniwien.ac.at](mailto:thomas.helbich@meduniwien.ac.at)  
Tel.: +43-1-404004819  
Fax: +43-1-404004898

I. Schreer  
Mammazentrum Klinik fuer  
Gynaekologie und Geburtshilfe,  
Universitätsklinikum Schleswig-  
Holstein Campus Kiel,  
Michaelisstr. 16,  
24105 Kiel, Germany  
e-mail: [ischreer@email.uni-kiel.de](mailto:ischreer@email.uni-kiel.de)  
Tel.: +49-431-5972100  
Fax: +49-431-5973617

**Abstract** The aim of the breast team is to obtain a definitive, nonoperative diagnosis of all potential breast abnormalities in a timely and cost-effective way. Percutaneous needle biopsy with its high sensitivity and specificity should now be standard practice, removing the need for open surgical biopsy or frozen section. For patients with cancer, needle biopsy provides a cost-effective and rapid way of providing not only a definitive diagnosis but prognostic information, allowing prompt discussion of treatment options, be they surgical or medical. Early removal of uncertainty

also allows better psychosocial adjustment to the disease. Patients with benign conditions found either by themselves or as a result of population or opportunistic screening can be promptly reassured and discharged, removing the health care and psychological costs of surgical biopsy or repeated follow-up. Radiologists involved in breast imaging should ensure that they have the necessary skills to carry out core biopsy and/or fine-needle aspiration (FNA) under all forms of image guidance. This paper provides guidelines on best practice for diagnostic interventional breast procedures and standards, against which all practitioners should audit themselves, from the European Society of Breast Imaging.

**Keywords** Breast cancer · Diagnostic imaging · Needle biopsy · Guidelines

### Introduction

The aim of the breast team is to obtain a definitive, nonoperative diagnosis of all potential breast abnormalities in a timely and most cost-effective way. Women with no significant breast problems should be reassured as quickly

as possible, and women with cancer should be diagnosed without delay.

The highest levels of diagnostic accuracy in the nonoperative diagnosis of breast disease are achieved by using a triple approach [1], which combines the results of clinical examination and imaging with fine-needle aspira-

tion cytology (FNAC) and/or core biopsy (both wide bore and vacuum-assisted) of significant breast abnormalities [2, 3]. When the results of all three modalities agree, the level of diagnostic accuracy exceeds 99% [4]. It is of interest to note that similar levels of accuracy have been obtained in the case of impalpable lesions, in which clinical examination is noncontributory [5].

Percutaneous needle biopsy with its high sensitivity and specificity should now be standard practice, removing the need for open surgical biopsy or frozen section [6–9]. For patients with cancer, needle biopsy provides a cost-effective and rapid way of providing not only a definitive diagnosis but prognostic information, allowing prompt discussion of treatment options, be they surgical or medical. Early removal of uncertainty also allows better psychosocial adjustment to the disease. It is not the goal of percutaneous biopsy to completely excise cancer.

Benign conditions found either by the patient themselves or as a result of population or opportunistic screening can be promptly reassured and discharged, removing the health care and psychological costs of surgical biopsy [10, 11]. The role of needle biopsy versus short-term follow up in the management of probably benign lesions is less clear cut. The American literature, where annual examinations are routine, suggests that there is no difference in the levels of stress or intention to reattend [12, 13]. On the other hand, in the UK NHS Breast Screening Programme, early recall is considered more stressful both in the short- and long-term than needle biopsy [14, 15]. Early follow-up is said to be

cheaper, but this might depend on individual health care economies and clinic organisation [16, 17]. The two options should be discussed with the patient, and if the triple approach confirms benignity, then the lesion can be reclassified as benign and the patient discharged. Radiologists involved in breast imaging should ensure that they have the necessary skills to carry out core biopsy and/or FNAC under stereotactic, ultrasound (US) and magnetic resonance imaging (MRI) control.

The aim of this paper is to provide guidelines for diagnostic interventional breast procedures by the European Society of Breast Imaging.

## Standards and objectives

Tables 1 and 2 provide a list of both outcome and process standards for interventional breast biopsy against which all individual practitioners and their multidisciplinary teams should audit themselves.

### Standard 1

This standard applies to all carcinomas (invasive and in situ) and applies to diagnoses made by FNAC and/or core biopsy vacuum-assisted biopsy. Only definitive diagnoses of malignancy should be included. Open surgical biopsy is not included.

**Table 1** Quality indicators (standards) for breast interventional procedures

Objective	Criteria	Acceptable standard	Desirable target
1 To ensure that the majority of cancers, both palpable and impalpable, receive a nonoperative tissue diagnosis of cancer	The percentage of women who have a nonoperative diagnosis of cancer by cytology or needle histology	>70%	>80%
2 To minimise the number of visits necessary to achieve a definitive diagnosis	The number of visits for interventional procedures	No more than 2	No more than 1
3 To minimise the number of unnecessary operative procedures	Ratio of benign:malignant biopsies	≤1:1	≤0.5:1
4 To achieve optimum aspiration technique and minimise the number of repeat needle biopsy procedures	Inadequate rate of NAC (all)	<25%	<15%
5 To maximise the nonoperative diagnosis rate and minimise the number of repeat needle biopsy procedures	Inadequate rate of FNAC from cancer	<10%	<5%
6 To maximise the nonoperative diagnosis rate and minimise the number of repeat needle biopsy procedures	Miss rate on core breast biopsy from cancer	<5%	<2%
7 To minimise understaging of invasive breast cancer	Percent of noninvasive core breast biopsies that are invasive at final surgery	<15%	<5%
8 To minimise understaging of breast cancer	Percent of high-risk core breast biopsies that are malignant at surgery	<25%	<10%

NAC needle aspiration cytology, FNAC fine-needle aspiration cytology

**Table 2** Quality indicators (standards) for breast interventional procedures (population screening)

Objective	Criteria	Acceptable standard	Desirable target
9 To minimise the number of unnecessary operative procedures	The rate of benign biopsies (when population screening)	Prevalent screen <3.6 per 1,000; incident screen <2.0 per 1,000	Prevalent screen <1.8 per 1,000; incident screen <1.0 per 1,000

## Standard 2

There is a risk that, in an attempt to drive up the nonoperative diagnostic rate, repeated attendances for needle biopsy during a single clinical episode are likely to be associated with unnecessary anxiety. A definitive diagnosis should be achieved in the minimum number of visits wherever possible.

To date, these standards and objectives have been laid down for screening programmes [18, 19] and, to a lesser extent, for referral (symptomatic) practice [20], but we have pulled them together and updated them. Each objective defines the purpose of the standard and has an accompanying criteria, which defines how the standard should be measured. The acceptable standard is a minimum that all teams should achieve. The desirable target is aspirational. We are aware that long-established teams and countries with population screening can comfortably attain these targets and, indeed, have national targets set at higher levels [18], but this only comes with considerable experience and the repeated use of audit [21]. We are confident that in a few years, we will be able to revisit and reset both the acceptable standard and the desirable target.

### Before interventional procedures

All patients should undergo a thorough workup including clinical examination and imaging prior to FNAC and/or core biopsy. The imaging characteristics of suspicious lesions are demonstrated using special views, including fine-focus magnification views for microcalcifications and spot compression views and US examination for mass lesions, focal asymmetry or architectural distortion. Imaging features of mammographically and/or US-detected abnormalities are assessed to determine the probability of malignancy, and this should be indicated in the radiological report. The radiologist must be certain that the abnormality seen on US is the same as the abnormality seen on mammography and, where relevant, that this corresponds to the palpable lesion. There should be written local protocols clearly defining the indications for FNAC, automated core biopsy and other needle biopsy techniques [2]. The procedure should be explained to the patient, with a brief explanation of risks and benefits. It should be standard practice to provide the patient with written information about complications.

### Teaching and experience

Training standards have been set out by the European Association of Radiology in the European Training Charter for Clinical Radiology (<http://www.eur-online.org>) [22]. We suggest that a minimum of 20 interventional procedures are undertaken under supervision (with histological verification) before commencing independent practice and then a minimum of 25 per year to maintain competence [23, 24].

### Choice of sampling technique

Current evidence suggests that, firstly, vacuum-assisted core biopsy (VACB) properly carried out provides better sensitivity and specificity than either 14-gauge core biopsy or FNAC for microcalcifications and architectural distortion. Secondly 14-gauge core biopsy provides better sensitivity and specificity than FNAC for other types of lesions [8, 9, 25, 26]. Core biopsy also facilitates definitive diagnosis of benign lesions [10, 11]. This has to be balanced against the cost and the fact that unless one uses imprint cytology [27, 28] or fast-track biopsy techniques [29] it is not possible to provide an answer immediately. Finally, core biopsy provides information on invasion, grade, hormone receptor status and other immunological and genetic markers. These can be used to assist in management decisions and aid in monitoring of the effects of neoadjuvant treatment [30]. In expert hands, remarkable results can be obtained on cytological specimens [31, 32].

FNAC may be preferred in some centres for sampling mass lesions and obvious carcinoma, but only where a satisfactory standard of excellence of both sampling and cytology interpretation has been achieved [8, 9, 33–35]. The main advantages of FNAC are cost [20, 33, 36] as one only requires 18- to 23-gauge disposable needles attached to a plastic syringe. Additional equipment includes glass slides with alcohol fixative for unsmear tissue samples [37]. Another advantage is the ability to provide immediate reporting, either on adequacy by a technician or a full diagnosis when a cytopathologist is available [25, 33, 38, 39]. While this is considered to be very beneficial for women with benign disease, it is less clear cut for patients with malignancy who need longer to come to terms with their diagnosis. The combination of the two techniques has been shown to be beneficial [40], particularly for cancer, as

FNAC allows for rapid diagnosis, which is subsequently confirmed by histology (core biopsy). This avoids the risk of a false positive diagnosis and obtains prognostic information for treatment decisions.

Needle size is important, with clear evidence that, when comparing 14-, 16- and 18-gauge needles, accuracy rises with needles of increasing size [41]. Long-throw needles used with a fully automated biopsy gun produce the best specimens [42–44]. Current best practice is to use a long-throw (2-cm) 14-gauge needle with biopsy gun (integral or separate).

VACB (from 8 to 11 gauge) can be used with either standard upright or prone stereotactic apparatus and under US guidance. Published evidence shows that the use of VACB is associated with higher rates of calcium retrieval and lower rates of underdiagnosis of both ductal carcinoma in situ (DCIS) and invasive tumour [25, 45, 46]. Where available, VACB may be considered the sampling method of choice for:

- Indeterminate cluster of microcalcifications
- Obviously malignant cluster of microcalcifications, to increase to the chance of detection of invasive foci
- Discordant results after 14-gauge core biopsy
- Architectural distortion
- Diagnostic excision of papillary lesions diagnosed at core biopsy

---

## Guidance

High proportions of mammographically detected lesions are impalpable and require image guidance for FNAC or core biopsy sampling. In addition, image guidance, particularly US, can have advantages over freehand procedures when sampling palpable lesions to ensure accurate and safe sampling [47, 48]. The choice of radiological guidance must be the method that (a) allows the best visualisation of the lesion, (b) offers the best chance of successful and adequate lesion sampling and (c) is the simplest and cheapest.

If a diagnostic MRI of the breast identifies a suspicious lesion, every effort should be made to reidentify the lesion on conventional modalities such as mammography or US [49]. If a lesion can be clearly identified on mammography or US, biopsy should be performed using one of these guiding modalities. However, second-look US fails to identify a sonographic correlate in up to 77% of MRI-detected lesions referred for biopsy [50, 51]. Where possible, MRI procedure should be undertaken with the same sequences used for the diagnostic study and, if time permits, in the second week of the menstrual cycle [52].

A clip should be placed at the end of the procedure to allow for mammographic marking if subsequent surgical intervention is indicated. Two orthogonal mammographic views are required to document the position of the clip.

## Complications

Complications from both FNAC and core biopsy are rare. However, the following have been reported:

- Pain
- Haematoma
- Fainting
- Pneumothorax [54]
- Infection [55]
- Seeding of tumour [56, 57, 60] (this does not appear to be of clinical significance)
- Removal of lesion by the core. (It is not the objective of the diagnostic biopsy to remove the lesion in its entirety; however, this will happen in the case of small lesions, and it is good practice to take a stereo film at 0° to check how much remains and, if needed, deploy a marker clip.)
- Dislocation of clip placement [53, 58]

---

## Adequacy of sampling

### FNAC sample

An adequate FNAC sample should contain at least five clusters of epithelial cells, each of which should contain five or more cells [2].

### Core biopsy

Generally, it is not appropriate to be dogmatic about the number of specimens taken when undertaking core biopsy, particularly when using US. The important thing is to achieve the targets set out above. Liberman [59, 60] suggests that a minimum of five passes are required. With experience, mass lesions can be diagnosed with a couple of passes [61]. However, it is necessary to obtain a representative sample adapted to lesion size and tissue consistency and document this. There should be radiological and pathological correlation before discussing the result with the patient. There are two specific lesion types in which more definitive evidence based guidance can be provided: microcalcification and architectural distortion.

### Microcalcifications

Representative microcalcification must be demonstrated in the core specimens on specimen radiography [45]. Identification of microcalcification on histology alone is not a reliable indicator of adequate sampling (histological microcalcification is a common incidental finding and can be present when there is no calcification visible on mammography) [62]. The literature is divided on how to

ensure optimal diagnostic accuracy: the minimalist approach of counting calcification on the specimen radiographs versus counting the number of cores or the volume removed. Bagnall [63] recommends that at least three flecks of calcification be seen in at least two cores. Ideally, five flecks or more should be seen in three cores. This requirement is obviously lessened in lesions with fewer than ten flecks of calcification. In these circumstances, a comparison before and after the procedure (scouts 0°) to evaluate the percentage of microcalcifications retrieved by the biopsies is indicated. Biopsies that retrieve more than 50% of the cluster can be considered as representative of the lesion [64]. On the other hand, Lomschitz [65] considers that when using 11-gauge VACB, 12 specimens (harvested by two rotations) gives maximum diagnostic yield.

If sampling is not adequate and/or in discordant radiohistological results, the procedure should be repeated or localisation surgical biopsy performed [46]. Surgical biopsy is not required when histology shows a definitively benign cause for calcifications in core specimens confirmed by specimen radiography to contain calcifications clearly representative of those considered suspicious on mammography.

Specificity and absolute sensitivity for sampling microcalcifications is significantly higher with the use of larger-bore biopsy devices, such as VACB, and such devices may be considered where there is diagnostic uncertainty [66, 67]. Surgical open biopsy is normally required to exclude frank malignant change in the adjacent tissues when histology shows indeterminate changes (e.g. hyperplasia with atypia) [45, 63], as even with large volume sampling, underestimation of disease will take place, i.e. hyperplasia on core is a harbinger of noninvasive disease, and some noninvasive core biopsies will turn out to be invasive on surgical treatment.

It is not the goal of percutaneous biopsy to completely excise cancer [64].

### Architectural distortion

Management of architectural distortion is still controversial, as 20–50% of cases of architectural distortion are due to malignancy [68]. Traditional teaching is that all these lesions should be removed. However, data from several published series now show that image-guided core biopsy is accurate in distinguishing malignant lesions from benign causes, e.g. radial scar, providing targeting is accurate and sufficient material is obtained [69–72]. A recent series has shown that the most accurate results are obtained by taking more than 12 11-gauge samples using a VACB device [73]. Recommendations for the management of architectural distortion depends on the local availability of vacuum-assisted mammotomy. If VACB is not available, it is recommended that conventional core biopsy is performed

as the initial diagnostic procedure on all distortions not due to surgical scarring [26]. If this shows malignant change, therapeutic surgery should be performed (a minimum of three cores targeted to sample different areas of the imaging abnormality). For all other diagnoses, diagnostic surgical open biopsy should be performed.

If VACB is available, it is recommended that initial diagnosis is carried out using conventional automated core biopsy. Again, a malignant result should be managed by therapeutic surgery. However if a result is benign or shows radial scar with no evidence of epithelial atypia, a choice of either open surgical excision or excision with VAB may be offered. VAB can be performed under US or stereotactic X-ray guidance, and a minimum of 12 11-gauge cores should be obtained. Where VAB is chosen and histology again shows either benign changes or radial scar with no evidence of epithelial atypia, then further excision is not required.

In all cases, management should be discussed prospectively by the multidisciplinary team. If there is doubt regarding concordance of the imaging/histology findings, diagnostic surgical excision should be recommended.

### Staging of the axilla

Sentinel lymph node biopsy (SLNB) has become rapidly accepted as an alternative to axillary sampling or clearance [74, 75]. Seven-year follow-up from Veronesi et al. suggests that this is a safe procedure [76]. Variable surgical and pathological practice indicates that there are still outstanding questions [75, 77]. Axillary node US with either FNAC or core biopsy can identify between 30% and 40% axillas with macroscopic disease [78–82] and according to Deurloo can reduce the number of SLNBs by up to 14% [80].

## Documentation

Images should be taken to document accurate needle placement. A written report to both the referring team and the reporting pathologist should include:

- Nature of lesion biopsied
- Radiological opinion and classification
- Details of procedure undertaken (including needle calibre)
- Adequacy of targeting
- Quantity of material sampled
- Presence or absence of microcalcification on specimen radiographs
- Changes (or not) of the lesion after biopsy (e.g. mass decreasing in size)
- Placement of a clip marker and description of its position

- Pathology centre where the specimen is being processed
- Complications (if any)

### After interventional procedures

#### Communication and discussion of result

Clinical examination, together with the result of imaging, must be considered with the results of needle biopsy to ensure clinico-radio-pathological concordance before management decisions are made. It is good practice that this occurs in a multidisciplinary fashion, preferably as part of a regular multidisciplinary meeting where full notes are taken or a written report is produced.

In addition to routine quality control tests, to ensure equipment safety and performance during imaging and interventional procedures, outcome data on the procedures should be collected. This data should be prospectively collected and summarised for each facility and physician who performs the procedures and by the reporting pathologist. In addition to data required to monitor performance against the standards outlined in the early part of the document, the number of complications, and the number of lesions requiring repeat biopsy and the reason should be recorded. A number of accreditation schemes are available [20, 81, 82].

### References

1. Lamb J, Anderson TJ, Dixon MJ, Levack P (1987) Role of fine needle aspiration cytology in breast cancer screening. *J Clin Pathol* 40:705–709
2. Cytology Sub-Group of the National Co-ordinating Committee for Breast Screening Pathology (1992) Guidelines for Cytology Procedures and Reporting in Breast Cancer Screening, Sheffield, NHS Breast Screening Programme (NHSBSP Publication No 22)
3. Britton P (1999) Fine needle aspiration or core biopsy. *Breast* 8:1–4
4. Zajdela A, Chossein NA, Pillerton JP (1975) The value of aspiration cytology in the diagnosis of breast cancer. *Cancer* 35:499–506
5. Azavedo E, Svane G, Auer G (1989) Stereotactic fine needle biopsy in 2594 mammographically detected non-palpable lesions. *Lancet* 1:1033–1035
6. Helbich TH, Matzek W, Fuchsjäger MH (2004) Stereotactic and Ultrasound guided breast biopsy. *Euro Radiol* 14 (3):383–393
7. Liberman L (2000) Centennial dissertation. Percutaneous image-guided core breast biopsy: state of the art at the millennium. *AJR Am J Roentgenol* 174:1191–1199
8. Britton P, McCann J (1999) Needle biopsy in the NHS Breast Screening Programme 1996/97: how much and how accurate? *Breast* 8:5–11
9. Berg WA, Hruban RH, Kumar D et al (1996) Lessons from mammographic-histopathologic correlation of large-core needle breast biopsy. *Radiographics* 16(5):1111–1130
10. Dixon JM, Clarke PJ, Cruciolli V, Lee EC, Greenhall MJ (1987) Reduction of the surgical excision rate in benign breast disease using fine needle aspiration cytology with immediate reporting. *Br J Surg* 75:1014–1016
11. Hosie KB, Cope A, Li Ting Wai P, Nottingham J, Wallis MG, Bishop HM (1994) Specialist Breast Surgeons perform less benign Breast Operations. *Breast* 3:215–217
12. Lindfors KK, O'Connor J, Acredolo CR, Liston SE (1998) Short-interval follow-up mammography versus immediate core biopsy of benign breast lesions: assessment of patient stress. *AJR Am J Roentgenol* 171:55–58
13. Currence BV, Pisano ED, Earp JA, Moore A, Chiu YF, Brown ME, Kurgat KL (2003) Does biopsy, aspiration or six month follow-up of a false-positive mammogram reduce future screening or have large psychosocial effects? *Acad Radiol* 10:1257–1266
14. Brett J, Austoker J, Ong G (1998) Do women who undergo further investigation for breast screening suffer adverse psychological consequences? A multi-centre follow-up study comparing different breast screening result groups five months after their last breast screening appointment. *J Public Health Med* 20:396–403
15. Brett J, Austoker J (2001) Women who are recalled for further investigations for breast screening: psychological consequences 3 years after recall and factors affecting re-attendance. *J Public Health Med* 23:292–300
16. Vizcaino I, Gadea L, Andreo L et al (2001) Short-term follow-up results in 795 non palpable probably benign lesions detected at screening mammography. *Radiology* 219:475–483
17. Helbich TH, Pfarrl G, Lomosschitz F, Stadler A, Rudas M, Wolf G (2000) Role of core needle breast biopsy in probably benign lesions. *Radiology* 219:475–483
18. Consolidated Guidance on Standards for the NHS Breast Screening Programme (2005) NHSBSP Publication 60(2)
19. European Guidelines for Quality Assurance in Mammography Screening (2001) 3rd Edition, Office for Official Publications of the European Communities
20. Perry NM (2001) Quality assurance in the diagnosis of breast disease. EU-SOMA Working Party. *Eur J Cancer* 37:159–172
21. An audit of screen detected breast cancers for the year of screening April 2003 to March 2004 Association of Breast Surgery at BASO (British Association of Surgical Oncology) report <http://www.cancerscreening.nhs.uk/breastscreen/publications/ba03-04.html>
22. European Training Charter for Clinical Radiology (2005) European Association of Radiology <http://www.eur.online.org>
23. Stufe-3-Leitlinie Brustkrebs-Früherkennung. <http://www.senologie.org> ISBN 3-88603-812-2
24. Liberman L, Benton CL, Dershaw DD, Abramson AF, LaTrenta LR, Morris EA (2001) Learning curve for stereotactic breast biopsy: how many cases are enough?. *AJR Am J Roentgenol* 176(3):721–727

25. Harcourt D, Ambler N, Rumsey N, Cawthorn SJ (1998) Evaluation of a one-stop breast lump clinic: a randomized controlled trial. *Breast* 7:314–319
26. Litherland JC, Evans AJ, Wilson ARM et al (1966) The impact of core-biopsy on pre-operative diagnosis rate of screen detected breast cancers. *Clin Radiol* 51:562–565
27. Jones L, Lott MF, Calder CJ, Kutt E (2004) Imprint cytology from ultrasound guided core biopsies: accurate and immediate diagnosis in a one stop breast clinic. *Clin Radiol* 59:903–908
28. Klevesath MB, Godwin RJ, Bannon R, Munthali L, Coveney E (2005) Touch imprint cytology of core needle biopsy specimens: a useful method for immediate reporting of symptomatic breast lesions. *Eur J Surg Oncol* 31(5):490–494
29. Ragazzini T, Magrini E, Cucchi MC, Foschini MP, Eusebi V (2005) The fast-track biopsy (FTB); description of a rapid histology and immunohistochemistry method for evaluation of preoperative breast core biopsies. *Int J Surg Pathol* 13(3):247–252
30. Gianna L, Zambretti M, Clark K et al (2005) Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. *J Clin Oncol* 23:7265–7277
31. Zafar N, Jamal S, Mamoon N, Luqman M, Anwar M (2005) Typing and grading of cytological category C5 breast lesions. *J Coll Physicians Surg Pak* 15:221–224
32. Hunt CM, Ellis IO, Elston CW et al (1990) Cytological grading of breast carcinomas—a feasible proposition? *Cytopathology* 1:287–295
33. Zagorianakou P, Fiaccavento S, Zagorianakou G, Makrydimas G, Agnantis NJ (2005) FNAC: Its role, limitations and perspective in the pre-operative diagnosis of breast cancer. *Eur J Gynaecol Oncol* 26:143–149
34. Abu-Salem OT (2002) Fine needle aspiration cytology (FNAB) of breast lumps: comparison study between pre- and post-operative histological diagnosis. *Arch Inst Pasteur Tunis* 79:59–63
35. Ljung B-M, Drejet A, Chiampi N et al (2001) Diagnostic accuracy of FNAC is determined by physician training in sampling technique. *Cancer* 93:263–268
36. Heywang-Köbrunner SH, Schreer I (eds.) (2003) *Bildgebende Mammadiagnostik. Untersuchungstechnik, Befundmuster und Differentialdiagnostik in Mammographie, Sonographie und Kernspintomographie*. Stuttgart: Thieme, second edition
37. Non-operative Sub-Group of the National Co-ordinating Committee for Breast Screening Pathology. Guidelines for non-operative diagnostic Procedures and Reporting in Breast Cancer Screening. Sheffield, NHS Breast Screening Programme (2001) NHSBSP Publication No 50:8–13
38. Nicholson S, Sainsbury JR, Wadehra V, Needham GK, Farndon JR (1998) Use of fine needle aspiration cytology with immediate reporting in the diagnosis of breast disease. *Br J Surg* 75:847–850
39. Dehn TC, Clarke J, Dixon JM, Cucchioli V, Greenhall, Lee EC (1987) Fine needle aspiration cytology, with immediate reporting, in the outpatient diagnosis of breast disease. *Ann R Coll Surg Engl* 69:280–282
40. Pilgrim S, Ravichandran D (2004) Fine needle aspiration cytology as an adjunct to core biopsy in the assessment of symptomatic breast cancer. *Breast* 14:411–414
41. Melotti MK, Berg WA (2001) Core needle breast biopsy in patients undergoing anticoagulation therapy: preliminary results. *AJR Am J Roentgenol* 174:245–249
42. Parker SH, Jobe WE, Dennis MA et al (1993) US-guided automated large-core breast biopsy. *Radiology* 187:507–511
43. Liberman L, Hann LE, Dershaw DD, Morris EA, Abramson AF, Rosen PP (1997) Mammographic findings after stereotactic 14-gauge vacuum biopsy. *Radiology* 203:343–347
44. Helbich TH, Rudas M, Haitel A, Kohlberger PD, Thurnher M, Gnant M, Wunderbaldinger P, Wolf G, Mostbeck GH (1998) Evaluation of needle size for breast biopsy: comparison of 14-, 16-, and 18-gauge biopsy needles. *AJR Am J Roentgenol* 171:59–63
45. Liberman L, Evans WP 3rd, Dershaw DD et al (1994) Radiography of microcalcifications in stereotaxic mammary core biopsy specimens. *Radiology* 190(1):223–225
46. Reynolds HE (2000) Core needle biopsy challenging benign breast conditions: a comprehensive literature review. *AJR Am J Roentgenol* 174:1245–1250
47. Lorenzen J, Welger J, Lisboa BW, Rietohof L, Grzyska B, Adam G (2002) Percutaneous core-needle biopsy of palpable breast tumours. Do we need ultrasound guidance? *Rofo* 174:1142–1146
48. Agarwal T, Patel B, Rajan P et al (2003) Core biopsy versus FNAC for palpable breast cancers. Is image guidance necessary? *Eur J Cancer* 39:52–56
49. LaTrenta LR, Menell JH, Morris EA, Abramson AF, Dershaw DD, Liberman L (2003) Breast lesions detected with MR imaging: utility and histopathologic importance of identification with US. *Radiology* 227(3):856–861
50. Dhamanaskar KP, Muradall D (2002) MRI directed ultrasound: a cost effective method for diagnosis and intervention in breast imaging [abstract]. *Radiology* 225:653
51. Panizza P, De Gaspari A (1997) Accuracy of post MR imaging second-look sonography in previously undetected breast lesions [abstract]. *Radiology* 205:489
52. Khul CK, Bieling HB, Gieseke J et al (1977) Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. *Radiology* 203:137–144
53. Burbank F, Forcier N (1997) Tissue marking clip for stereotactic breast biopsy: initial placement accuracy, long-term stability, and usefulness as a guide for wire localization. *Radiology* 205:407–415
54. Catania S, Boccato P, Bono A et al (1989) Pneumothorax: a rare complication of fine needle aspiration of the breast. *Acta Cytol* 33(1):140
55. Witt A, Yavuz D, Walchetseder C, Strohmer H, Kubista E (2003) Preoperative core needle biopsy as an independent risk factor for wound infection after breast surgery. *Obstet Gynecol* 101(4):745–750
56. Liberman L, Vuolo M, Dershaw DD et al (1999) Epithelial displacement after stereotactic 11-gauge directional vacuum-assisted breast biopsy. *AJR Am J Roentgenol* 172:677–681
57. Preece PE, Hunter SM, Duigood HLD, Wood RAB (1998) Cytodiagnosis and other methods of biopsy in the modern management of breast cancer. *Sem Surg Oncol* 5:69–81
58. Pfarl G, Helbich TH, Riedl CC, Guth-Wagner T, Gnant M, Rudas M, Liberman L (2002) Stereotactic 11-gauge vacuum-assisted breast biopsy: a validation study. *AJR Am J Roentgenol* 179:1503–1507
59. Liberman L, Dershaw DD, Rosen PP, Abramson AF, Deutch BM, Hann LE (1994) Stereotactic 14-gauge breast biopsy: how many core biopsy specimens are needed? *Radiology* 192:793–795

60. Liberman L, Smolkin JH, Dershaw DD, Morris EA, Abramson AF, Rosen PP (1998) Calcification retrieval at stereotactic, 11-gauge, directional, vacuum-assisted breast biopsy. *Radiology* 208:251–260
61. Fishman JE, Milikowski C, Ramsinghani R, Velasquez V, Aviram G (2003) US-guided core-needle biopsy of the breast: how many specimens are necessary? *Radiology* 226:779–782
62. Rosen EL, Bentley RC, Baker JA, Scott, Soo M (2002) Image-guided core needle biopsy of papillary lesions of the breast. *AJR Am J Roentgenol* 179:1185–1192
63. Bagnall MJC, Evans AJ, Wilson ARM et al (2000) When have mammographic calcifications been adequately sampled at core biopsy? *Clin Radiol* 55:543–548
64. Liberman L, Kaplan JB, Morris EA, Abramson AF, Menell JH, Dershaw DD (2002) To excise or to sample the mammographic target: what is the goal of stereotactic 11-gauge vacuum-assisted breast biopsy? *AJR Am J Roentgenol* 179:679–683
65. Lomosschitz FM, Helbich TH, Rudas M, Stadler A, Pfarl G, Wolf G (2000) Stereotactic directional vacuum assisted breast biopsy: How many specimens do we need? *Radiology* 217:527
66. Liberman L, Sarna MP (2000) Cost effectiveness of stereotactic 11-gauge directional vacuum-assisted breast biopsy. *AJR Am J Roentgenol* 175:53–58
67. Teh WL, Shah BKS, Michell MJ et al Prospective randomised study of stereotactic breast biopsy using 14G core biopsy and 11G vacuum-assisted biopsy: The UK Mammotome trial. *Clin Rad* (in press)
68. Mayers MM, Sloane JP (1993) Carcinoma and atypical hyperplasia in radial scars and complex sclerosing lesions: importance of lesion size and patient age. *Histopathology* 23:225–231
69. Philpotts LE, Shaheen NA, Jain KS, Carter D, Lee CH (2000) Uncommon high-risk lesions of the breast diagnosed at stereotactic core-needle biopsy: clinical importance. *Radiology* 216:831–837
70. Dennis MA, Parker S, Kaske TI, Stavros AT, Camp J (2000) Incidental treatment of nipple discharge caused by intraduct papilloma through diagnostic mammotome biopsy. *AJR Am J Roentgenol* 174:1263–1268
71. Cawson JN, Frank M, Kavanagh A, Hill P, Balasubramaniam G, Henderson M (2003) Fourteen-gauge needle core biopsy of mammographically evident radial scars: is excision necessary? *Cancer* 97(2):345–351
72. Kirwan SE, Denton ERE, Nash RM, Humphreys S, Michell MJ (2000) Multiple 14G stereotactic core biopsies in the diagnosis of mammographically detected stellate lesions of the breast. *Clin Radiol* 55:763–766
73. Brenner RJ, Jackman RJ, Parker SH et al (2002) Percutaneous core needle biopsy of radial scars of the breast: when is excision necessary? *AJR Am J Roentgenol* 179:1179–1184
74. Collins CD (2005) The sentinel node in breast cancer: an update. *Cancer Imaging* 5: Spec No A:S3–S9
75. Kim T, Giuliano AE, Lyman GH (2006) Lymphatic mapping and sentinel lymph node biopsy in early-stage breast cancer. *Cancer* 1:4–16
76. Veronesi U, Galimberti V, Mariani L, Gatti G, Paganelli G et al (2005) Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection. *Eur J Cancer* 41:197–198
77. Viale G, Mastropasqua MG, Maiorano E, Mazzarol G (2005) Pathological examination of the axillary sentinel lymphnodes with early-stage breast carcinoma: current and resolving controversies on the basis of the European Institute of Oncology experience. *Virchows Archiv* 448(3):241–247
78. Damera A, Evans AJ, Cornford EJ, Wison AR, Burrell HC et al (2003) Diagnosis of axillary nodal metastases by ultrasound core biopsy in primary operable breast cancer. *Br J Cancer* 89:1310–1313
79. Keuen-Boumeester V, Menke-Pluymers M, de Kanter AY, Obdeijn IM et al (2003) Ultrasound-guided fine needle aspiration cytology of axillary lymph nodes in breast cancer patients. A preoperative staging procedure. *Eur J Cancer* 39:170–174
80. Deurloo EE, Tanis PJ, Gilhuijs KG, Muller SH, Kroger R et al (2003) Reduction in the number of sentinel node procedures by preoperative ultrasonography of the axilla in breast cancer. *Eur J Cancer* 39:1037–1038
81. Helbich TH, Buchberger W, Rudas M (2002) Österreichisches Konsensuspapier: Stereotaktisch und Ultraschallgezielte Vakuumbiopsie von Brustläsionen. *Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr* 174:517–521
82. American College of Radiology (2003) Illustrated breast imaging reporting and data system (BI-RADS™). 4th edition. Reston, VA: American College of Radiology